Drugs / 177Lu-LNC1010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05410743 | Jun 2022 → Mar 2025 | — | The First Affiliated Hospital of Xiamen University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-LNC1010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05410743 ↗ |
| Known as | 177Lu-EB-TATE-01 | “177Lu-LNC1010(177Lu-EB-TATE-01) is a radiotherapeutic drug indicated in subjects with unresectable, metastatic somatostatin receptor (SSTR) positive tumors.” NCT05410743 ↗ |
| Action | Inhibit | “SSTR antagonists, such as LNC1010, have emerged as a new type of somatostatin analog” NCT05410743 ↗ |
| Modality | Peptide | “long-lasting radiolabeled somatostatin analogue based peptide receptor radionuclide therapy” NCT05410743 ↗ |
| Route | Intravenous | “will be injected intravenously” NCT05410743 ↗ |